Factor VIIa Regulates the Expression of Caspase-3, MMP-9, and CD44 in SW620 Colon Cancer Cells Involving PAR2/MAPKs/NF-κB Signaling Pathways

REFERENCES

• Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005;26:1–43.
   PubMed Web of Science ®Google Scholar
• Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase activated receptors. Pharmacol Rev 2001;53:245–282.
   PubMed Web of Science ®Google Scholar
• Kirkland JG, Cottrell GS, Bunnett NW, Corvera CU. Agonists of protease-activated receptors 1 and 2 stimulate electrolyte secretion from mouse gallbladder. Am J Physiol Gastrointest Liver Physiol 2007;293:G335–G346.
   PubMed Web of Science ®Google Scholar
• Bushell T. The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders. J Physiol 2007;581:7–16.
   PubMed Web of Science ®Google Scholar
• Zhou H, Hu H, Shi W, Ling S, Wang T, Wang H. The expression and the functional roles of tissue factor and protease-activated receptor-2 on SW620 cells. Oncol Rep 2008;20:1069–1076.
   PubMed Web of Science ®Google Scholar
• Zhou H, Shi W, Zhou B, Guo D, Wang T. Tissue factor-factor VIIa regulates interleukin-8, tissue factor and caspase-7 expression in SW620 cells through protease-activated receptor-2 activation. Mol Med Rep 2010;3:269–274.
   Web of Science ®Google Scholar
• Guo D, Zhou H, Wu Y, Zhou F, Xu G, Wen H, Zhang X. Involvement of ERK1/21/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620. Tumor Biol 2011;32:921–930.
   PubMed Web of Science ®Google Scholar
• Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734–1741.
   PubMed Web of Science ®Google Scholar
• Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004;53:153–159.
   PubMed Web of Science ®Google Scholar
• Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, Paradiso A, Quaranta M. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res 2010;30:3521–3527.
   PubMed Web of Science ®Google Scholar
• Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS. CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol 2007;31:1119–1126.
   PubMed Web of Science ®Google Scholar
• Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res 2002;107:271–276.
   PubMed Web of Science ®Google Scholar
• Ruf W. Tissue factor and PAR signaling in tumor progression. Thromb Res 2007;120(suppl 2):S7–S12.
   PubMedGoogle Scholar
• Awasthi V, Mandal SK, Papanna V, Rao LV, Pendurthi UR. Modulation of tissue factor-factor Vlla signaling by lipid rafts and caveolae. Arterioscler Thromb Vasc Biol 2007;27:1447–1455.
   PubMed Web of Science ®Google Scholar
• Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol 2009;29:1999–2004.
   PubMed Web of Science ®Google Scholar
• Sørensen BB, Freskgård PO, Nielsen LS, Rao LV, Ezban M, Petersen LC. Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem 1999;274:21349–21354.
   PubMed Web of Science ®Google Scholar
• Zerbib P, Grimonprez A, Corseaux D, Mouquet F, Nunes B, Petersen LC, Susen S, Ung A, Hebbar M, Pruvot FR, Chambon JP, Jude B. Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer. J Surg Res 2009;153:239–245.
   PubMedGoogle Scholar
• Hector S, Prehn J. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 2009;1795:117–129.
   PubMed Web of Science ®Google Scholar
• Groblewska M, Mroczko B, Szmitkowski M. The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development. Postepy Hig Med Dosw 2010;64:22–30.
   Web of Science ®Google Scholar
• Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14: 6751–60.
   PubMed Web of Science ®Google Scholar
• Åberg M, Wickström M, Siegbahn A. Simvastatin induces apoptosis in human breast cancer cells in a NFκB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res 2008;122:191–202.
   PubMed Web of Science ®Google Scholar
• Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor Vlla. Blood 2003;102:1708–1715.
   PubMed Web of Science ®Google Scholar
• Hahn N, Heiden M, Seitz R, Salge-Bartels U. Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion. J Cancer Res Clin Oncol 2012;138:695–703.
   PubMed Web of Science ®Google Scholar
• Xue M, Chan YK, Shen K, Dervish S, March L, Sambrook PN, Jackson CJ. Protease activated receptor (PAR) 2, rather than PAR1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2012;64:88–98.
   PubMed Web of Science ®Google Scholar
• Suen JY, Gardiner B, Grimmond S, Fairlie DP. Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS One 2010;5:e13809.
   Google Scholar
• McCoy KL, Traynelis SF, Hepler JR. PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology. Mol Pharmacol 2010;77:1005–1015.
   Google Scholar
• Lim JW, Kim H. Role of protease-activated receptor-2 on cell death and DNA fragmentation in Helicobacter pylori-infected gastric epithelial cells. J Transl Med 2010;8:85–92.
   PubMedGoogle Scholar
• Wang S, Quang LT, Chida J, Cisse Y, Yano M, Kido H. Mechanisms of matrix metalloproteinase-9 upregulation and tissue destruction in various organs in influenza A virus infection. J Med Invest 2010;57:26–34.
   PubMedGoogle Scholar
• Itatsu K, Sasaki M, Harada K, Yamaguchi J, Ikeda H, Sato Y, Ohta T, Sato H, Nagino M, Nimura Y, Nakanuma Y. Phosphorylation of extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase and nuclear translocation of nuclear factor-kappaB are involved in upregulation of matrix metalloproteinase-9 by tumor necrosis factor-alpha. Liver Int 2009;29: 291–298.
   PubMed Web of Science ®Google Scholar
• Robbins EW, Travant EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer 2008;8:260–269.
   PubMedGoogle Scholar
• Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP. Novel agonists and antagonists for human protease activated receptor 2. J Med Chem 2010;53:7428–7440.
   PubMed Web of Science ®Google Scholar
• Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, Fairlie DP. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol 2012;165:1413–1423.
   PubMed Web of Science ®Google Scholar